



FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
**SAY HELLO TO CLEARER SKIN.
SAY HELLO TO TREMFYA™.**

IN CLINICAL STUDIES AT 16 WEEKS,

AT LEAST 7 OUT OF 10
PATIENTS SAW 90%
**CLEARER
SKIN**

**MORE THAN 80%
WERE RATED
CLEARED
OR ALMOST CLEARED**

INDIVIDUAL RESULTS MAY VARY

TREMFYA™ is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA™ is not for everyone; only your doctor can decide if it's right for you. TREMFYA™ is a prescription medicine that affects your immune system and may cause serious side effects, including infections, and may increase your risk of infections. Please read the Important Safety Information on page 7 and the Medication Guide for TREMFYA™ to learn more about these and other risks for TREMFYA™. Discuss any questions you have with your doctor.

INTRODUCING TREMFYA™



If you've tried it all for your moderate to severe plaque psoriasis—steroids, topical creams, or phototherapy and still didn't get the results you wanted—then TREMFYA™ may be what you're waiting for.

CLEARER SKIN AFTER JUST 3 DOSES

IN CLINICAL STUDIES AT 16 WEEKS,

<p>AT LEAST 7 OUT OF 10 PATIENTS SAW 90% CLEARER SKIN</p>	<p>MORE THAN 80% WERE RATED CLEARED OR ALMOST CLEARED</p>
--	--

INDIVIDUAL RESULTS MAY VARY

CLEARER SKIN THAT LASTS

In a clinical study, **nearly 9 out of 10 people** who saw at least 90% clearer skin at 28 weeks continued to see at least 90% clearer skin at 48 weeks while on TREMFYA™.



INDIVIDUAL RESULTS MAY VARY

SUPERIOR RESULTS

In a head-to-head clinical study over 48 weeks, more patients treated with TREMFYA™ achieved clearer skin vs patients treated with Humira® (adalimumab), today's most commonly prescribed medication for moderate to severe plaque psoriasis:

NEARLY 2X

WEEK 48: 47% of people taking TREMFYA™ achieved cleared skin vs 24% of Humira® patients—nearly twice as many.

Results reflective of patients studied in the U.S. and Canada.

FEWER SYMPTOMS

More people using TREMFYA™ were free from symptoms, including itching, skin tightness, burning, stinging, and pain, at 24 weeks compared with those using Humira®.



INDIVIDUAL RESULTS MAY VARY

FEWER DOSES

With only 1 maintenance dose every 8 weeks (after 2 starter doses at weeks 0 and 4), that's about 2 whole months that you don't have to think about your treatment schedule.

TREMFYA™ is administered as a single 100 mg injection under the skin at weeks 0 and 4 and then every 8 weeks. It is administered by a healthcare provider or self-injected only after proper training.

Humira® is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate. Humira® is a registered trademark of AbbVie Inc.

FIRST 52 WEEKS OF THERAPY

<p>TREMFYA™</p> <p>8</p> <p>DOSES</p> <p>1 DOSE EVERY 8 WEEKS (after 2 starter doses at weeks 0 and 4)</p>	<p>HUMIRA®</p> <p>27</p> <p>DOSES</p> <p>1 DOSE EVERY OTHER WEEK (starting 1 week after the first dose of 80 mg)</p>
---	---

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA™ is not for everyone; only your doctor can decide if it's right for you. TREMFYA™ is a prescription medicine that affects your immune system and may cause serious side effects, including infections, and may increase your risk of infections. Please read the Important Safety Information on page 7 and the Medication Guide for TREMFYA™ to learn more about these and other risks for TREMFYA™. Discuss any questions you have with your doctor.

HOW TREMFYA™ WORKS

TREMFYA™ is the first and only approved biologic to selectively block interleukin-23 (IL-23), one of the key proteins thought to be responsible for plaque psoriasis.



What is a biologic?

Biologics are medicines that work to target an overactive immune system, a possible cause of plaque psoriasis. Most biologics for plaque psoriasis, including TREMFYA™, are given as an injection under your skin. It is administered by a healthcare provider or self-injected only after proper training.

TREMFYA™ AND SCALP PSORIASIS

In clinical studies at 16 weeks, 4 out of 5 people with scalp psoriasis were rated cleared or almost cleared after just 3 doses.



**4 OUT OF 5 PEOPLE
RATED CLEARED**
OR ALMOST CLEARED OF SCALP PSORIASIS

Simply put, TREMFYA™ can give you results you can see and feel.

RESULTS: WEEK 16 AND WEEK 48

Actual Patient from VOYAGE2 Trial

WEEK 0



WEEK 16



WEEK 48



Individual results may vary. Photos are of a real patient from VOYAGE 2 who received TREMFYA™ 100 mg at weeks 0, 4, and 12.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA™ is not for everyone; only your doctor can decide if it's right for you. TREMFYA™ is a prescription medicine that affects your immune system and may cause serious side effects, including infections, and may increase your risk of infections. Please read the Important Safety Information on page 7 and the Medication Guide for TREMFYA™ to learn more about these and other risks for TREMFYA™. Discuss any questions you have with your doctor.

A SUCCESSFUL CONVERSATION STARTS WITH YOU

Communicating openly with your dermatologist is the first step to better managing your moderate to severe plaque psoriasis.

Your dermatologist is relying on you to tell them about your experience with plaque psoriasis. Answer a few simple questions about your symptoms and how they affect you using our Dermatologist Conversation Starter. Then bring it to your provider so you can have a more open discussion about what you're looking for in your new treatment for moderate to severe plaque psoriasis.

DESCRIBE YOUR EXPERIENCE

How satisfied are you with your current levels of symptom control?

- Very satisfied
- Somewhat satisfied
- Neutral
- Somewhat unsatisfied
- Very unsatisfied

How often do you have symptoms of plaque psoriasis?


- Every other week
- Every month
- Every few months
- Other _____

In your day-to-day life, how bothered are you by your moderate to severe plaque psoriasis symptoms (e.g., itching, skin tightness, burning, stinging, and pain)?



TREMFYA™ is not for everyone. You and your dermatologist can decide if TREMFYA™ is right for you. Individual results may vary.

Where on your body do you experience your symptoms?



SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA™ is not for everyone; only your doctor can decide if it's right for you. TREMFYA™ is a prescription medicine that affects your immune system and may cause serious side effects, including infections, and may increase your risk of infections. Please read the Important Safety Information on page 7 and the Medication Guide for TREMFYA™ to learn more about these and other risks for TREMFYA™. Discuss any questions you have with your doctor.

YOU HAVE A PRESCRIPTION, WHAT'S NEXT?

This may be a good time to ask if you qualify for the PsO Simple Trial Program, offered by Janssen CarePath. The PsO Simple Trial Program provides you with your first dose of TREMFYA™, at no cost, along with helpful support through the first 30 days of treatment.

SUPPORT FOR YOU: THE JANSSEN CAREPATH TEAM



Janssen CarePath provides information you may need to help you get started and stay on track once your doctor has prescribed TREMFYA™.

Your Janssen CarePath Care Coordinator can:

- Review your health plan benefits to help answer questions about insurance coverage
- Work with your specialty pharmacy to process and deliver your TREMFYA™ medication to your doctor's office or home
- Connect you with Janssen Nurse Support for information about your injection

INSURANCE COVERAGE



If you are starting TREMFYA™, your dermatologist's office will check to see what your insurance covers.

No matter what type of insurance you have, Janssen CarePath can help explain your medication insurance coverage and benefits.

**\$20,000 maximum program benefit per calendar year. Not valid for patients using Medicare, Medicaid, or any other federally funded programs to pay for TREMFYA™. There is no income requirement. Visit JanssenCarePath.com/patient/TREMFYA for full eligibility requirements.*

HELP IF YOUR INSURANCE PLAN DOES NOT APPROVE TREMFYA™ TREATMENT

If you are delayed or denied treatment from your insurance provider, you may be eligible to receive TREMFYA™ at no cost through the Janssen Link program. Call a Janssen CarePath Care Coordinator at 877-CarePath (877-227-3728), Monday–Friday, 8 AM–8 PM ET for more information.

If you are using government insurance or do not have insurance coverage, JanssenPrescriptionAssistance.com provides information on affordability programs.

INJECTION SUPPORT



A NURSE IS JUST A PHONE CALL AWAY

Even after you've been trained by a healthcare professional to give yourself an injection, you may still have questions. Janssen Nurse Support can answer questions about giving yourself an injection at home, preparing your injection site prior to self-injecting, and properly disposing of your used syringe.



Janssen Nurse Support

Call 877-CarePath (877-227-3728)

Monday–Friday | 9 AM–8 PM ET

At all other times, a nurse will return your call in about 15 minutes



Visit JanssenCarePath.com



STORING YOUR SYRINGE

Store in original carton until time of use, protect from light until use. Store TREMFYA™ in your refrigerator at 36 °F to 46 °F. Do not freeze. Do not shake. Discard any unused portion. TREMFYA™ is sterile and preservative free.

COST SUPPORT OPTIONS



If you are eligible, you may be able to lower your out-of-pocket costs. With the Janssen CarePath Savings Program, eligible patients pay just \$5 for each dose for your TREMFYA™ medication costs, with a \$20,000 maximum program benefit each calendar year.



CONVENIENT DISPOSAL OF YOUR USED SYRINGES

Dispose of your prefilled syringe in a puncture-resistant container (FDA-cleared sharps disposal container). Do not reuse needles or syringes. Safe Returns® is a simple, safe, and convenient way to dispose of your used syringes—at no additional cost to you. When you sign up, you'll receive a Safe Returns® plastic disposal container in the mail, along with simple mail-back instructions.

Call 877-CarePath (877-227-3728), Monday–Friday, 8 AM–8 PM ET to sign up for the Safe Returns® program.



SUPPORT, ENCOURAGEMENT, AND TREATMENT REMINDERS

Support and encouragement are available by calling Janssen CarePath or visiting JanssenCarePath.com. Also, we understand how important it is for you to take your TREMFYA™ medication just as your doctor prescribed. That's why we offer tools to remind you when your next dose of TREMFYA™ is due, to help you stay on track.

To get started, call: 877-CarePath (877-227-3728), Monday–Friday, 8 AM–8 PM ET

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA™ is not for everyone; only your doctor can decide if it's right for you. TREMFYA™ is a prescription medicine that affects your immune system and may cause serious side effects, including infections, and may increase your risk of infections. Please read the Important Safety Information on page 7 and the Medication Guide for TREMFYA™ to learn more about these and other risks for TREMFYA™. Discuss any questions you have with your doctor.

THE TREMFYA™ TIMELINE: YEAR 1

Use this timeline to find the information you're looking for, whether you're waiting to get your prescription filled or want to see what sort of results you could see as you go through your treatment.

TREMFYA™ is administered as a single 100 mg injection under the skin at weeks 0 and 4 and then every 8 weeks. It is administered by a healthcare provider or self-injected only after proper training.



I HAVE A PRESCRIPTION. WHAT HAPPENS NOW?

After your healthcare provider prescribes TREMFYA™, their office coordinator will confirm your insurance coverage.



MEET JANSSEN CAREPATH

Explore our support services and see everything we can do to help you. For more on Janssen CarePath, see page 5.



THE FIRST STARTER DOSE

Your first injection may be performed at your dermatologist's office, so he or she can make sure you're properly trained to self-inject at home.



THE SECOND STARTER DOSE

You're on your way!



THE FIRST MAINTENANCE DOSE

Next one in 8 weeks!



WEEK 16

After just 3 doses, at least 7 out of 10 patients saw at least 90% clearer skin, and more than 80% were rated as cleared or almost cleared at 16 weeks. Individual results may vary.



THE SECOND MAINTENANCE DOSE

Keep up the great work!

CONTINUED ON THE RIGHT



WEEK 24

In 2 clinical studies, TREMFYA™ outperformed Humira®, today's most commonly prescribed medication for moderate to severe plaque psoriasis:

STUDY 1: 80% of TREMFYA™ patients reported at least 90% clearer skin vs 44% using Humira® at week 24.

STUDY 2: More than 70% of TREMFYA™ patients reported at least 90% clearer skin vs approximately half of patients receiving Humira® at week 24.



THE THIRD MAINTENANCE DOSE

Keep on going!



THE FOURTH MAINTENANCE DOSE

Be sure to keep in touch with your dermatologist or Janssen CarePath with any questions.



THE FIFTH MAINTENANCE DOSE

You're nearly done with year 1.



WEEK 48

After 48 weeks, nearly twice as many people taking TREMFYA™ achieved cleared skin vs Humira®*, today's most commonly prescribed medication for moderate to severe plaque psoriasis.

*TREMFYA™ 47% vs Humira® 24%.



THE SIXTH MAINTENANCE DOSE

You've finished your first year with TREMFYA™!



WE'RE ALWAYS HERE TO HELP

Janssen CarePath Care Coordinators are here to help as you continue your journey with TREMFYA™.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA™ is not for everyone; only your doctor can decide if it's right for you. TREMFYA™ is a prescription medicine that affects your immune system and may cause serious side effects, including infections, and may increase your risk of infections. Please read the Important Safety Information on page 7 and the Medication Guide for TREMFYA™ to learn more about these and other risks for TREMFYA™. Discuss any questions you have with your doctor.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TREMFYA™?

TREMFYA™ may cause serious side effects, including infections.

TREMFYA™ is a prescription medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with TREMFYA™ and may treat you for TB before you begin treatment with TREMFYA™ if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with TREMFYA™.

- Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
 - fever, sweats, or chills
 - muscle aches
 - weight loss
 - cough
 - warm, red, or painful skin or sores on your body different from your psoriasis
 - diarrhea or stomach pain
 - shortness of breath
 - blood in your phlegm (mucus)
 - burning when you urinate or urinating more often than normal

Before using TREMFYA™, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section “**What is the most important information I should know about TREMFYA™?**”
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with TREMFYA™.
- are pregnant or plan to become pregnant. It is not known if TREMFYA™ can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if TREMFYA™ passes into your breast milk.

Tell your healthcare provider about all the medicines you take,

including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TREMFYA™?

TREMFYA™ may cause serious side effects. See “What is the most important information I should know about TREMFYA™?”

The most common side effects of TREMFYA™ include:

upper respiratory infections, headache, injection site reactions, joint pain (arthralgia), diarrhea, stomach flu (gastroenteritis), fungal skin infections, and herpes simplex infections.

These are not all the possible side effects of TREMFYA™. Call your doctor for medical advice about side effects.

Use TREMFYA™ exactly as your healthcare provider tells you to use it.

Please read the full Prescribing Information, including Medication Guide for TREMFYA™, and discuss any questions that you have with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.



ASK YOUR DERMATOLOGIST ABOUT RESULTS WITH TREMFYA™.

TREMFYA™ is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).

FOR MORE INFORMATION



Visit TREMFYAinfo.com

janssen
CarePath

Call 877-CarePath (877-227-3728)

Monday–Friday | 8 AM–8 PM ET

Visit JanssenCarePath.com

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA™ is not for everyone; only your doctor can decide if it's right for you. TREMFYA™ is a prescription medicine that affects your immune system and may cause serious side effects, including infections, and may increase your risk of infections. Please read the Important Safety Information on page 7 and the Medication Guide for TREMFYA™ to learn more about these and other risks for TREMFYA™. Discuss any questions you have with your doctor.

© Janssen Biotech, Inc. 2017 08/17 075830-170707